PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26429859-6	2015	Here, we show that a novel pan-HDACi AR-42 downregulates CD44, a glycoprotein that has been associated with lenalidomide and dexamethasone resistance in myeloma both in vitro and in vivo.	Lenalidomide	108-120	CD44 molecule (Indian blood group)	Homo sapiens	57-61	
31423579-0	2020	JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.	Lenalidomide	92-104	CD44 molecule (Indian blood group)	Homo sapiens	130-134	
28643330-5	2017	LEN resistance has been linked to activation of the WNT/beta-catenin CD44 pathway.	Lenalidomide	0-3	CD44 molecule (Indian blood group)	Homo sapiens	69-73	
26429859-9	2015	Thus, our findings shed light on potential novel combinatorial therapeutic approaches modulating CD44 expression, which may help overcome lenalidomide resistance in myeloma patients.	Lenalidomide	138-150	CD44 molecule (Indian blood group)	Homo sapiens	97-101	
23760401-0	2014	Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.	Lenalidomide	73-85	CD44 molecule (Indian blood group)	Homo sapiens	23-27	
23760401-2	2014	Lenalidomide-resistant models were found to overexpress the hyaluronan (HA)-binding protein CD44, a downstream Wnt/beta-catenin transcriptional target.	Lenalidomide	0-12	CD44 molecule (Indian blood group)	Homo sapiens	92-96	
23760401-3	2014	Consistent with a role of CD44 in cell adhesion-mediated drug resistance (CAM-DR), lenalidomide-resistant myeloma cells were more adhesive to bone marrow stroma and HA-coated plates.	Lenalidomide	83-95	CD44 molecule (Indian blood group)	Homo sapiens	26-30	
23760401-4	2014	Blockade of CD44 with monoclonal antibodies, free HA or CD44 knockdown reduced adhesion and sensitized to lenalidomide.	Lenalidomide	106-118	CD44 molecule (Indian blood group)	Homo sapiens	12-16	
23760401-4	2014	Blockade of CD44 with monoclonal antibodies, free HA or CD44 knockdown reduced adhesion and sensitized to lenalidomide.	Lenalidomide	106-118	CD44 molecule (Indian blood group)	Homo sapiens	56-60	
23760401-8	2014	Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.	Lenalidomide	87-99	CD44 molecule (Indian blood group)	Homo sapiens	57-61